The molecular biology firm joins the Tobacco Dock event to showcase its clinical approach to NAD+ restoration and cellular healthspan.
In an era where the supplement aisle is increasingly cluttered with the latest “must-have” molecules, Nuchido arrives with a refreshing commitment to the rigors of molecular biology. The UK-based firm, which has carved out a distinct niche within the crowded NAD+ landscape, will join the upcoming Longevity Show at Tobacco Dock as a Catalyst Partner. While many in the sector are content to chase the latest longevity “trends,” Nuchido has spent the better part of a decade quietly interrogating the mechanics of cellular decline; it is an approach that prioritizes biological logic over marketing-led shortcuts.
Rather than treating the body as a passive vessel to be “topped up” with external precursors, Nuchido’s philosophy is rooted in the belief that the most effective longevity interventions are those that restore the body’s innate capacity for self-repair. By moving away from the simplistic “replacement” model, the company’s flagship formulation, Nuchido TIME+ is helping to define a new era of geroscience where the goal is not merely to supplement, but to reactivate the dormant machinery of youth.
Longevity.Technology: The NAD+ sector has matured beyond the initial excitement of simple precursors, yet it remains a crowded marketplace where consumer confusion often reigns supreme; Nuchido distinguishes itself by eschewing the “top-up” model in favor of a sophisticated systems-biology approach. By targeting NAMPT – the rate-limiting enzyme in the salvage pathway – and inhibiting the inflammatory CD38 “drain,” the company addresses the fundamental cellular mechanics of decline rather than merely treating the symptom of depletion. It is refreshing to see a partner lead with randomized, double-blind, placebo-controlled human data in a category frequently criticized for its reliance on “borrowed” science. Dr Nichola Conlon’s presence at the Longevity Show as both a keynote and discovery stage speaker offers a vital opportunity for attendees to look under the hood of cellular metabolism; her research-first philosophy sets a necessary benchmark for the industry – proving that restoration is far more elegant than simple replacement. Science, not trends.
Addressing the root causes of NAD+ decline
The fundamental challenge of aging at a cellular level is not merely the loss of vital molecules, but the breakdown of the pathways that produce them. Central to Nuchido’s strategy is the upregulation of NAMPT, the rate-limiting enzyme responsible for the NAD+ salvage pathway. As we age, NAMPT levels dwindle, leaving cells unable to recycle the raw materials needed for energy production and DNA repair [1]. By pairing this upregulation with the inhibition of CD38 – an inflammatory enzyme known to “drain” cellular resources – Nuchido offers a dual-action intervention that is as scientifically robust as it is innovative.
Clinical transparency and the path to Tobacco Dock
This evidence-first philosophy is underpinned by randomized, double-blind, placebo-controlled human clinical trials, which have demonstrated significant increases in cellular NAD+ levels alongside improvements in key markers of aging, including inflammation, glycation and biological age [2]. It is this level of clinical transparency that elevates Nuchido above the fray. Attendees at the Longevity Show will have the opportunity to engage directly with this data, moving beyond the anecdotal to the analytical.
Commenting on the partnership, Phil Newman, CEO of Longevity.Technology, noted: “We’re thrilled to welcome Nuchido as a Catalyst Partner for The Longevity Show because they turn cutting-edge longevity science into real-world impact. Their clinically validated work on restoring NAD+ and cellular health shows how rigorous research can be translated into products that help extend healthspan, not just lifespan. Led by molecular biologist Dr Nichola Conlon, Nuchido is a gold-standard example of science-first longevity innovation, perfectly aligned with our mission to scale health and longevity at this year’s Tobacco Dock event and beyond.”
Unpacking the biology
The educational component of the partnership is perhaps its most significant value-add. Nuchido’s founder, Dr Nichola Conlon, will take to the stage twice during the event – once as a headline keynote speaker and again on the discovery stage. During her session, NAD+: Separating the hype from the science, the longevity scientist will navigate the complexities of one of the most discussed molecules in the sector, unpacking its central role in cellular health and its influence on biological age. The talk is designed to move beyond the headlines, explaining the underlying mechanics of NAD+ decline and providing attendees with the critical eye necessary to navigate the increasingly crowded landscape of boosting interventions.
Her sessions are expected to pull back the curtain on cellular metabolism, offering a masterclass in how geroscience can be translated into practical, daily protocols. For Nuchido, the event represents a pivotal moment to bridge the gap between the laboratory and the living room.
“At Nuchido, our mission has always been to bridge the gap between cutting-edge longevity science and everyday health, through both our products and our commitment to education,” says Conlon. “That’s why it’s so encouraging to see the UK increasingly embrace this space, with events like the Longevity Show creating a platform to bring together innovative products and expert speakers.”
To learn more about partnership and exhibitor opportunities at The Longevity Show 2026, contact the Sponsor & Exhibitor team.
The Longevity Show opens its doors on 26–27 June 2026 at Tobacco Dock, London. Tickets for all tiers are now available at www.longevityshow.com.
Photographs courtesy of Nuchido
[1] https://www.researchgate.net/publication/306312038_It_takes_two_to_tango_NAD_and_sirtuins_in_aginglongevity_control
[2] https://www.nature.com/articles/s41514-023-00134-0
